Aortic stenosis and angiotensin-converting enzyme inhibitors—Rupture of an ancient paradigm?

The extended recommendation is not to use angiotensin-converting enzyme (ACE) in this particular valvulopathy because the risk of first-dose hypotension due to a sudden decrease in the systemic vascular resistance in a patient with fixed cardiac output (CO).

Saved in:
Bibliographic Details
Published in:The American heart journal 2005-02, Vol.149 (2), p.E5-E5
Main Authors: Barrera-Ramírez, Carlos F., Pineda-Pompa, Luis R., Ilarraza, Hermes
Format: Article
Language:English
Subjects:
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Aortic Valve Stenosis - complications
Aortic Valve Stenosis - drug therapy
Drug therapy
Enzymes
Heart failure
Humans
Hypotension - complications
Pulmonary arteries
Vasodilator Agents - adverse effects
Vasodilator Agents - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The extended recommendation is not to use angiotensin-converting enzyme (ACE) in this particular valvulopathy because the risk of first-dose hypotension due to a sudden decrease in the systemic vascular resistance in a patient with fixed cardiac output (CO).
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2004.09.044